Why Ocugen Stock Will Probably Soar Tomorrow -- but Shouldn't

Moderna's shares have more than tripled in value so far this year. BioNTech has been an even bigger winner for investors. Buying and holding the stocks of leading COVID-19 vaccine makers has turned out to be a pretty good strategy.

But there's one vaccine stock that has outperformed them all in 2021. Shares of Ocugen (NASDAQ: OCGN) have skyrocketed close to 550% year to date. Here's why the stock will probably soar even more tomorrow -- but shouldn't. 

Image source: Getty Images.

Continue reading

Source Fool.com